Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2026

Summary of Financial Information with Respect to Reportable Segments

Presented below is financial information with respect to the Company’s reportable segments for the periods presented:


	Three Months Ended March 31,
	2026		2025
Segment revenues(1):
Software	$	35,560	$	48,816
Drug discovery	23,027		10,735
Total segment revenues	58,587		59,551
Segment cost of revenues(1):
Software	12,300		13,522
Drug discovery	16,740		14,905
Total segment cost of revenues	29,040		28,427
Segment gross profit:
Software	23,260		35,294
Drug discovery	6,287		(4,170)
Total segment gross profit	29,547		31,124
Unallocated (expense) income:
Research and development	(43,824)		(45,844)
Sales and marketing	(11,603)		(10,367)
General and administrative	(22,914)		(25,802)

Change in fair value of equity investments	(13,487)		(13,095)
Other income	2,663		4,204
Income tax expense	(408)		(28)
Consolidated net loss	$	(60,026)	$	(59,808)

(1) Contribution activity is included within the segments to which the contribution activity relates as software contribution activity and drug discovery contribution activity share similar economic characteristics, respectively, with the software and drug discovery segments.

Schedule of Revenues by Geographic Area

Revenues by geographic area are determined based on the address provided by the Company's customers and partners. The following table sets forth revenues by geographic area for the three months ended March 31, 2026 and 2025:


	Three Months Ended March 31,
	2026		2025
United States	$	31,408	$	29,663
EMEA	20,173		23,083
APAC	6,673		6,074
Rest of World	333		731
	$	58,587	$	59,551